Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV/AIDS
Pharma
Gilead's bictegravir, lenacapavir tablet meets mark in phase 3
For people who are on multi-tablet HIV regimens, many of whom are also on drugs for other conditions, the findings are "significant," an expert said.
Eric Sagonowsky
Nov 13, 2025 9:55am
Gilead campaign urges people living with HIV to 'Choose U'
Sep 4, 2025 11:55am
Gilead's PrEP shows early promise in once-yearly dosing
Mar 11, 2025 2:30pm
GSK’s ViiV plots next steps to fight HIV in Black communities
Feb 7, 2025 1:58pm
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
Gilead’s twice-yearly PrEP drug shows 100% efficacy
Jun 20, 2024 11:45am
